Avalo (AVTX) Achieves Positive Phase 2 Results for Abdaikibart and Madrigal (MDGL) Acquires RNAi Candidate for MASH Treatment
Avalo's Abdaikibart Shows Promise in Phase 2 Trial
Avalo Therapeutics (AVTX) announced positive Phase 2 (LOTUS) results for abdaikibart (AVTX-009) in patients with moderate-to-severe hidradenitis suppurativa (HS). This IL-1ฮฒ-targeting antibody demonstrated a response rate of 42.2% and 42.9% in the 150mg and 300mg dose groups, respectively, after 16 weeks of treatment, compared to 25.6% in the placebo group. Following this success, the company launched a $375 million public offering to fund a Phase 3 trial. This new treatment option is expected to compete with UCB's Bimzelx for patients.
BioNTech to Scale Down Manufacturing and Reduce Workforce
BioNTech (BNTX) has decided to close three manufacturing facilities in Germany and Singapore, as well as CureVac's entire manufacturing operations, and reduce its workforce by approximately 1,860 employees to reduce costs and improve efficiency. This decision is aimed at overcoming the decline in vaccine demand and focusing resources on the commercialization of its next-generation mRNA-based cancer therapies. The restructuring is expected to save the company over โฌ500 million annually starting in 2029, allowing it to strengthen its R&D efforts. The industry views this as a shift from a vaccine-focused company to an oncology-focused biotech.
Madrigal Expands MASH Pipeline
Madrigal Pharmaceuticals (MDGL) has acquired global rights to ARO-PNPLA3, an RNA interference (RNAi) candidate for the treatment of MASH (metabolic dysfunction-associated steatohepatitis), from Arrowhead (ARWR). The agreement includes an upfront payment of $25 million and potential milestone payments of up to $975 million. This decision is aimed at leveraging the synergies with its existing approved drug, Rezdiffra. The candidate targets a gene variant found in Hispanic patients, potentially offering a new precision medicine approach. This strategic move is intended to solidify Madrigal's position in the MASH market.
Johnson & Johnson Advances Dual-Targeting Antibody in Clinical Trials
Johnson & Johnson (JNJ) has released the results of the Phase 2b (DUET) trial for JNJ-4804, a dual-targeting antibody being developed for the treatment of inflammatory bowel disease (IBD). While the drug failed to achieve the primary endpoint, it demonstrated a meaningful clinical response rate in patients with refractory IBD who had failed prior treatments. In particular, the drug showed a response rate of 50.8% in Crohn's disease patients, which is higher than that of single-agent therapies, and the company has confirmed that it will move forward with a Phase 3 trial. This is seen as an effort to maximize convenience and efficacy by combining multiple therapies into a single formulation.
Avalo's (AVTX) abdaikibart demonstrated a response rate of 42.9% in the Phase 2 trial, which is significantly higher than the placebo group (25.6%), securing a strong competitive position in the hidradenitis suppurativa market, which is expected to grow to $2.2 billion by 2030. This demonstrates superior clinical trial design compared to previous failures by companies like Moonlake and Insmed, and the $375 million raised through a public offering will provide the momentum to accelerate the Phase 3 trial. Furthermore, Madrigal's (MDGL) acquisition of ARO-PNPLA3 from Arrowhead for a total of $1 billion reflects the industry's strategic trend of strengthening its pipeline and solidifying its market dominance with existing approved drugs. BioNTech's (BNTX) reduction of 1,860 employees and closure of manufacturing facilities, along with Johnson & Johnson's (JNJ) decision to proceed with the Phase 3 trial of its IBD combination antibody JNJ-4804, demonstrate the long-term business transformation of companies focusing on cost efficiency and reallocating resources to late-stage and unmet medical needs.
Source: BioPharma Dive (rss)